UK markets close in 7 hours 7 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
82.93-0.22 (-0.26%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close83.15
Open82.15
Bid82.77 x 800
Ask0.00 x 900
Day's range81.80 - 83.24
52-week range65.25 - 92.64
Volume6,614,914
Avg. volume7,882,400
Market cap209.75B
Beta (5Y monthly)0.47
PE ratio (TTM)20.21
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.44 (2.94%)
Ex-dividend date14 Sep 2020
1y target estN/A
  • EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers
    Reuters

    EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

    Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe. The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca has developed with Merck & Co Inc as it faces competition from British rival GlaxoSmithKline on cancer drugs.

  • Seattle Genetics Up on Two New Oncology Deals With Merck
    Zacks

    Seattle Genetics Up on Two New Oncology Deals With Merck

    Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

  • Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
    Zacks

    Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

    Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more